0.29 USD
▼-0.02-6.18%
盘后 0.28 -2.51%
2026-11-20
市值
$4.75M
市盈率
—
EPS
-3.38
股息率
—
52 周区间
0.28 – 4.75
成交量
155.51K
Beta
-1.56
目标价
—
52W 低 0.2852W 高 4.75
价格走势
公司简介
Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma that completed Phase 2 clinical trial; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating various cancers. The company has a collaboration agr...